ENSG00000162613 |
FUBP1 |
anaplastic oligodendroglioma |
sequence_alteration |
19.28% (48/249) |
5 entries |
ENSG00000162613 |
FUBP1 |
colorectal adenocarcinoma |
missense_variant |
2.997% (35/1168) |
2 entries |
ENSG00000162613 |
FUBP1 |
cecum adenocarcinoma |
missense_variant |
4.943% (13/263) |
2 entries |
ENSG00000162613 |
FUBP1 |
anaplastic oligodendroglioma |
stop_gained |
19.28% (48/249) |
7 entries |
ENSG00000162613 |
FUBP1 |
cecum adenocarcinoma |
frameshift_variant |
4.943% (13/263) |
2 entries |
ENSG00000162613 |
FUBP1 |
colorectal adenocarcinoma |
frameshift_variant |
2.997% (35/1168) |
3 entries |
ENSG00000162613 |
FUBP1 |
colon adenocarcinoma |
missense_variant |
3.489% (44/1261) |
5 entries |
ENSG00000162613 |
FUBP1 |
colon adenocarcinoma |
frameshift_variant |
3.489% (44/1261) |
3 entries |
ENSG00000162613 |
FUBP1 |
anaplastic oligodendroglioma |
missense_variant |
19.28% (48/249) |
2 entries |
ENSG00000162613 |
FUBP1 |
anaplastic oligodendroglioma |
frameshift_variant |
19.28% (48/249) |
8 entries |
ENSG00000162613 |
FUBP1 |
colon adenocarcinoma |
sequence_alteration |
3.489% (44/1261) |
3 entries |
ENSG00000162613 |
FUBP1 |
colorectal adenocarcinoma |
sequence_alteration |
2.997% (35/1168) |
1 entry |
ENSG00000162613 |
FUBP1 |
cecum adenocarcinoma |
sequence_alteration |
4.943% (13/263) |
1 entry |
ENSG00000162613 |
FUBP1 |
urothelial carcinoma |
frameshift_variant |
4.651% (4/86) |
1 entry |
ENSG00000162613 |
FUBP1 |
breast ductal adenocarcinoma |
missense_variant |
0.8531% (14/1641) |
1 entry |
ENSG00000162613 |
FUBP1 |
colon adenocarcinoma |
stop_gained |
3.489% (44/1261) |
1 entry |
ENSG00000162613 |
FUBP1 |
brain glioblastoma |
sequence_alteration |
0.7988% (11/1377) |
4 entries |
ENSG00000162613 |
FUBP1 |
esophageal squamous cell carcinoma |
missense_variant |
1.308% (9/688) |
4 entries |
ENSG00000162613 |
FUBP1 |
rectal adenocarcinoma |
stop_gained |
0.9158% (5/546) |
1 entry |
ENSG00000162613 |
FUBP1 |
bile duct adenocarcinoma |
missense_variant |
0.5141% (2/389) |
2 entries |
ENSG00000162613 |
FUBP1 |
skin melanoma |
missense_variant |
1.293% (15/1160) |
3 entries |
ENSG00000162613 |
FUBP1 |
prostate adenocarcinoma |
missense_variant |
0.8841% (19/2149) |
2 entries |
ENSG00000162613 |
FUBP1 |
osteosarcoma |
sequence_alteration |
1.948% (3/154) |
2 entries |
ENSG00000162613 |
FUBP1 |
oligoastrocytoma |
frameshift_variant |
6.25% (5/80) |
2 entries |
ENSG00000162613 |
FUBP1 |
chronic lymphocytic leukemia |
stop_gained |
1.205% (11/913) |
2 entries |
ENSG00000162613 |
FUBP1 |
clear cell renal carcinoma |
frameshift_variant |
0.4003% (6/1499) |
2 entries |
ENSG00000162613 |
FUBP1 |
small cell lung carcinoma |
stop_gained |
0.905% (4/442) |
2 entries |
ENSG00000162613 |
FUBP1 |
lung adenocarcinoma |
sequence_alteration |
0.9456% (24/2538) |
1 entry |
ENSG00000162613 |
FUBP1 |
prostate adenocarcinoma |
sequence_alteration |
0.8841% (19/2149) |
1 entry |
ENSG00000162613 |
FUBP1 |
melanoma |
missense_variant |
2.055% (3/146) |
2 entries |
ENSG00000162613 |
FUBP1 |
skin melanoma |
frameshift_variant |
1.293% (15/1160) |
1 entry |
ENSG00000162613 |
FUBP1 |
bladder transitional cell carcinoma |
missense_variant |
1.525% (7/459) |
1 entry |
ENSG00000162613 |
FUBP1 |
anaplastic oligodendroglioma |
transcript_ablation |
19.28% (48/249) |
1 entry |
ENSG00000162613 |
FUBP1 |
Endometrial Endometrioid Adenocarcinoma |
missense_variant |
1.855% (12/647) |
1 entry |
ENSG00000162613 |
FUBP1 |
lobular breast carcinoma |
frameshift_variant |
1.158% (3/259) |
2 entries |
ENSG00000162613 |
FUBP1 |
urothelial carcinoma |
missense_variant |
4.651% (4/86) |
1 entry |
ENSG00000162613 |
FUBP1 |
anaplastic oligoastrocytoma |
sequence_alteration |
3.81% (4/105) |
2 entries |
ENSG00000162613 |
FUBP1 |
prostate carcinoma |
frameshift_variant |
1.643% (7/426) |
1 entry |
ENSG00000162613 |
FUBP1 |
bladder transitional cell carcinoma |
stop_gained |
1.525% (7/459) |
1 entry |
ENSG00000162613 |
FUBP1 |
hemangioblastoma |
sequence_alteration |
11.43% (4/35) |
1 entry |
ENSG00000162613 |
FUBP1 |
Endometrial Endometrioid Adenocarcinoma |
frameshift_variant |
1.855% (12/647) |
1 entry |
ENSG00000162613 |
FUBP1 |
esophageal adenocarcinoma |
sequence_alteration |
1.463% (8/547) |
1 entry |
ENSG00000162613 |
FUBP1 |
clear cell renal carcinoma |
sequence_alteration |
0.4003% (6/1499) |
2 entries |
ENSG00000162613 |
FUBP1 |
breast carcinoma |
missense_variant |
0.3795% (6/1581) |
1 entry |
ENSG00000162613 |
FUBP1 |
lung adenocarcinoma |
stop_gained |
0.9456% (24/2538) |
1 entry |
ENSG00000162613 |
FUBP1 |
chronic lymphocytic leukemia |
sequence_alteration |
1.205% (11/913) |
1 entry |
ENSG00000162613 |
FUBP1 |
brain glioblastoma |
missense_variant |
0.7988% (11/1377) |
3 entries |
ENSG00000162613 |
FUBP1 |
prostate carcinoma |
sequence_alteration |
1.643% (7/426) |
1 entry |
ENSG00000162613 |
FUBP1 |
ovarian serous adenocarcinoma |
missense_variant |
1.074% (9/838) |
1 entry |
ENSG00000162613 |
FUBP1 |
chronic lymphocytic leukemia |
frameshift_variant |
1.205% (11/913) |
1 entry |
ENSG00000162613 |
FUBP1 |
diffuse large B-cell lymphoma |
stop_gained |
1.078% (4/371) |
2 entries |
ENSG00000162613 |
FUBP1 |
Duodenal Adenocarcinoma |
frameshift_variant |
17.65% (3/17) |
1 entry |
ENSG00000162613 |
FUBP1 |
squamous cell lung carcinoma |
missense_variant |
1.073% (10/932) |
2 entries |
ENSG00000162613 |
FUBP1 |
clear cell renal carcinoma |
missense_variant |
0.4003% (6/1499) |
1 entry |
ENSG00000162613 |
FUBP1 |
lung adenocarcinoma |
missense_variant |
0.9456% (24/2538) |
5 entries |
ENSG00000162613 |
FUBP1 |
rectal adenocarcinoma |
missense_variant |
0.9158% (5/546) |
2 entries |
ENSG00000162613 |
FUBP1 |
brain glioblastoma |
frameshift_variant |
0.7988% (11/1377) |
1 entry |
ENSG00000162613 |
FUBP1 |
anaplastic astrocytoma |
missense_variant |
0.5128% (1/195) |
1 entry |
ENSG00000162613 |
FUBP1 |
oligoastrocytoma |
sequence_alteration |
6.25% (5/80) |
1 entry |
ENSG00000162613 |
FUBP1 |
alveolar rhabdomyosarcoma |
frameshift_variant |
3.125% (2/64) |
1 entry |
ENSG00000162613 |
FUBP1 |
papillary thyroid carcinoma |
frameshift_variant |
0.5917% (3/507) |
1 entry |
ENSG00000162613 |
FUBP1 |
neoplasm of mature B-cells |
frameshift_variant |
1.667% (1/60) |
1 entry |
ENSG00000162613 |
FUBP1 |
endometrium adenocarcinoma |
missense_variant |
3.704% (1/27) |
1 entry |
ENSG00000162613 |
FUBP1 |
breast carcinoma |
stop_gained |
0.3795% (6/1581) |
1 entry |
ENSG00000162613 |
FUBP1 |
prostate carcinoma |
missense_variant |
1.643% (7/426) |
1 entry |
ENSG00000162613 |
FUBP1 |
bladder transitional cell carcinoma |
frameshift_variant |
1.525% (7/459) |
1 entry |
ENSG00000162613 |
FUBP1 |
marginal zone B-cell lymphoma |
sequence_alteration |
3.333% (1/30) |
1 entry |
ENSG00000162613 |
FUBP1 |
anaplastic oligoastrocytoma |
frameshift_variant |
3.81% (4/105) |
1 entry |
ENSG00000162613 |
FUBP1 |
small cell lung carcinoma |
missense_variant |
0.905% (4/442) |
1 entry |
ENSG00000162613 |
FUBP1 |
testicular seminoma |
missense_variant |
1.282% (1/78) |
1 entry |
ENSG00000162613 |
FUBP1 |
hemangioblastoma |
frameshift_variant |
11.43% (4/35) |
1 entry |
ENSG00000162613 |
FUBP1 |
melanoma |
stop_gained |
2.055% (3/146) |
1 entry |
ENSG00000162613 |
FUBP1 |
anaplastic astrocytoma |
sequence_alteration |
0.5128% (1/195) |
1 entry |
ENSG00000162613 |
FUBP1 |
carcinoid tumor |
missense_variant |
25.0% (1/4) |
1 entry |
ENSG00000162613 |
FUBP1 |
basal cell carcinoma |
stop_gained |
2.941% (2/68) |
1 entry |
ENSG00000162613 |
FUBP1 |
hepatocellular carcinoma |
frameshift_variant |
0.5071% (5/986) |
1 entry |
ENSG00000162613 |
FUBP1 |
ovarian serous adenocarcinoma |
sequence_alteration |
1.074% (9/838) |
1 entry |
ENSG00000162613 |
FUBP1 |
oral squamous cell carcinoma |
missense_variant |
0.7634% (2/262) |
1 entry |
ENSG00000162613 |
FUBP1 |
anaplastic astrocytoma |
stop_gained |
0.5128% (1/195) |
1 entry |
ENSG00000162613 |
FUBP1 |
Merkel cell skin cancer |
stop_gained |
1.064% (1/94) |
1 entry |
ENSG00000162613 |
FUBP1 |
papillary thyroid carcinoma |
missense_variant |
0.5917% (3/507) |
1 entry |
ENSG00000162613 |
FUBP1 |
diffuse large B-cell lymphoma |
missense_variant |
1.078% (4/371) |
1 entry |
ENSG00000162613 |
FUBP1 |
diffuse gastric adenocarcinoma |
missense_variant |
1.22% (1/82) |
1 entry |
ENSG00000162613 |
FUBP1 |
non-small cell lung carcinoma |
stop_gained |
0.9615% (1/104) |
1 entry |
ENSG00000162613 |
FUBP1 |
oral squamous cell carcinoma |
stop_gained |
0.7634% (2/262) |
1 entry |
ENSG00000162613 |
FUBP1 |
skin melanoma |
sequence_alteration |
1.293% (15/1160) |
1 entry |
ENSG00000162613 |
FUBP1 |
Mixed Lobular and Ductal Breast Carcinoma |
missense_variant |
1.562% (1/64) |
1 entry |
ENSG00000162613 |
FUBP1 |
Ampulla of Vater Carcinoma |
sequence_alteration |
2.353% (2/85) |
1 entry |
ENSG00000162613 |
FUBP1 |
acute myeloid leukemia |
missense_variant |
0.3304% (3/908) |
1 entry |
ENSG00000162613 |
FUBP1 |
renal carcinoma |
stop_gained |
5.0% (1/20) |
1 entry |
ENSG00000162613 |
FUBP1 |
gastric intestinal type adenocarcinoma |
missense_variant |
1.176% (1/85) |
1 entry |
ENSG00000162613 |
FUBP1 |
basal cell carcinoma |
missense_variant |
2.941% (2/68) |
1 entry |
ENSG00000162613 |
FUBP1 |
alveolar rhabdomyosarcoma |
missense_variant |
3.125% (2/64) |
1 entry |
ENSG00000162613 |
FUBP1 |
osteosarcoma |
missense_variant |
1.948% (3/154) |
1 entry |
ENSG00000162613 |
FUBP1 |
prostate adenocarcinoma |
frameshift_variant |
0.8841% (19/2149) |
1 entry |
ENSG00000162613 |
FUBP1 |
small cell lung carcinoma |
sequence_alteration |
0.905% (4/442) |
1 entry |
ENSG00000162613 |
FUBP1 |
breast carcinoma |
frameshift_variant |
0.3795% (6/1581) |
1 entry |
ENSG00000162613 |
FUBP1 |
Ampulla of Vater Carcinoma |
missense_variant |
2.353% (2/85) |
1 entry |
ENSG00000162613 |
FUBP1 |
anaplastic oligoastrocytoma |
stop_gained |
3.81% (4/105) |
1 entry |
ENSG00000162613 |
FUBP1 |
oligoastrocytoma |
stop_gained |
6.25% (5/80) |
1 entry |
ENSG00000162613 |
FUBP1 |
schwannoma |
missense_variant |
25.0% (1/4) |
1 entry |
ENSG00000162613 |
FUBP1 |
papillary thyroid carcinoma |
sequence_alteration |
0.5917% (3/507) |
1 entry |
ENSG00000162613 |
FUBP1 |
lung adenocarcinoma |
frameshift_variant |
0.9456% (24/2538) |
1 entry |
ENSG00000162613 |
FUBP1 |
esophageal squamous cell carcinoma |
stop_gained |
1.308% (9/688) |
1 entry |
ENSG00000162613 |
FUBP1 |
diffuse large B-cell lymphoma |
sequence_alteration |
1.078% (4/371) |
1 entry |